MicroRNAs associated with therapy of non-small cell lung cancer

BACKGROUND & OBJECTIVE The incidence of non-small cell lung cancer (NSCLC) has been rising over the past several decades. Despite various therapeutic regimens and modern diagnostic techniques are developed, NSCLC still have an extremely poor prognosis due to drug resistance. Therefore, it is critical to find a novel precise diagnosis and effective treatment approach for NSCLC patients. MicroRNAs (MiRNAs) are a class of 18-25nt non-coding small RNAs, which have been shown to be involved profoundly in the pathogenesis such as cellular proliferation, differentiation, development, apoptosis and tumorigenesis in many human tumors including of NSCLC. We reviewed existing research literature regarding correlations between miRNAs and their target's response to anticancer treatment, and summarized the recent findings between miRNAs and therapy availability in NSCLC.

[1]  S. Fan,et al.  Roles of microRNAs in the resistance to platinum based chemotherapy in the non-small cell lung cancer , 2017, Journal of Cancer.

[2]  Baoli Hu,et al.  miR-181c contributes to cisplatin resistance in non-small cell lung cancer cells by targeting Wnt inhibition factor 1 , 2017, Cancer Chemotherapy and Pharmacology.

[3]  Jifeng Feng,et al.  MicroRNA-106b-5p regulates cisplatin chemosensitivity by targeting polycystic kidney disease-2 in non-small-cell lung cancer , 2017, Anti-cancer drugs.

[4]  S. Fan,et al.  Long non-coding RNAs associated with non-small cell lung cancer , 2017, Oncotarget.

[5]  Zhengxiang Shan,et al.  MicroRNA-92a promotes epithelial-mesenchymal transition through activation of PTEN/PI3K/AKT signaling pathway in non-small cell lung cancer metastasis. , 2017, International journal of oncology.

[6]  Li-na Peng,et al.  miR-181b-5p mediates TGF-β1-induced epithelial-to-mesenchymal transition in non-small cell lung cancer stem-like cells derived from lung adenocarcinoma A549 cells , 2017, International journal of oncology.

[7]  C. Gridelli,et al.  Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: A systematic review of recently published studies , 2017, PloS one.

[8]  F. Alongi,et al.  Stage-I small cell lung cancer: A new potential option for stereotactic ablative radiation therapy? A review of literature. , 2017, Critical reviews in oncology/hematology.

[9]  A. Nielsen,et al.  MET amplification and epithelial-to-mesenchymal transition exist as parallel resistance mechanisms in erlotinib-resistant, EGFR-mutated, NSCLC HCC827 cells , 2017, Oncogenesis.

[10]  Guan-Jhong Huang,et al.  3,4-Dihydroxybenzalactone Suppresses Human Non-Small Cell Lung Carcinoma Cells Metastasis via Suppression of Epithelial to Mesenchymal Transition, ROS-Mediated PI3K/AKT/MAPK/MMP and NFκB Signaling Pathways , 2017, Molecules.

[11]  N. Villegas-Sepúlveda,et al.  Tumor suppressor miR-29c regulates radioresistance in lung cancer cells , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[12]  Gang Chen,et al.  Clinical value of miR-145-5p in NSCLC and potential molecular mechanism exploration: A retrospective study based on GEO, qRT-PCR, and TCGA data , 2017, Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine.

[13]  Shuxu Zhang,et al.  Disturbance of the let-7/LIN28 double-negative feedback loop is associated with radio- and chemo-resistance in non-small cell lung cancer , 2017, PloS one.

[14]  Yanjing Wang,et al.  Up-regulation of miR-146a increases the sensitivity of non-small cell lung cancer to DDP by downregulating cyclin J , 2017, BMC Cancer.

[15]  Hongbing Shen,et al.  Downregulation of miR-218 contributes to epithelial–mesenchymal transition and tumor metastasis in lung cancer by targeting Slug/ZEB2 signaling , 2017, Oncogene.

[16]  Sze Chuen Cesar Wong,et al.  MiR-30 Family Potentially Targeting PI3K-SIAH2 Predicted Interaction Network Represents a Novel Putative Theranostic Panel in Non-small Cell Lung Cancer , 2017, Frontiers in genetics.

[17]  Xiao-Feng Li,et al.  Suppression of EIF4G2 by miR‐379 potentiates the cisplatin chemosensitivity in nonsmall cell lung cancer cells , 2017, FEBS letters.

[18]  S. Fan,et al.  The role of microRNAs in resistance to targeted treatments of non-small cell lung cancer , 2017, Cancer Chemotherapy and Pharmacology.

[19]  Jinmei Li,et al.  miR-135b reverses chemoresistance of non-small cell lung cancer cells by downregulation of FZD1. , 2016, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[20]  Bin Zhou,et al.  Pathologically decreased expression of miR-193a contributes to metastasis by targeting WT1-E-cadherin axis in non-small cell lung cancers , 2016, Journal of experimental & clinical cancer research : CR.

[21]  E. Buratti,et al.  Circulating Plasma MicroRNAs As Diagnostic Markers for NSCLC , 2016, Front. Genet..

[22]  L. Pan,et al.  MiR-21 and MiR-155 promote non-small cell lung cancer progression by downregulating SOCS1, SOCS6, and PTEN , 2016, Oncotarget.

[23]  Dejia Li,et al.  The Novel miR-9600 Suppresses Tumor Progression and Promotes Paclitaxel Sensitivity in Non–small-cell Lung Cancer Through Altering STAT3 Expression , 2016, Molecular therapy. Nucleic acids.

[24]  Wei Liu,et al.  miR-200c regulates crizotinib-resistant ALK-positive lung cancer cells by reversing epithelial-mesenchymal transition via targeting ZEB1 , 2016, Molecular medicine reports.

[25]  D. Goldstein,et al.  Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence , 2016, OncoTargets and therapy.

[26]  Zhang Jx,et al.  MicroRNA-132 inhibits migration, invasion and epithelial-mesenchymal transition by regulating TGFβ1/Smad2 in human non-small cell lung cancer. , 2016, European review for medical and pharmacological sciences.

[27]  L. Ling,et al.  miR-143 suppresses the proliferation of NSCLC cells by inhibiting the epidermal growth factor receptor. , 2016, Experimental and therapeutic medicine.

[28]  Wei Ma,et al.  Up- regulation of miR-328-3p sensitizes non-small cell lung cancer to radiotherapy , 2016, Scientific Reports.

[29]  N. Seki,et al.  MicroRNAs in non-small cell lung cancer and idiopathic pulmonary fibrosis , 2016, Journal of Human Genetics.

[30]  Wei Zhang,et al.  Attenuated LKB1-SIK1 signaling promotes epithelial-mesenchymal transition and radioresistance of non–small cell lung cancer cells , 2016, Chinese journal of cancer.

[31]  Baosheng Li,et al.  miR‐134 inhibits non‐small cell lung cancer growth by targeting the epidermal growth factor receptor , 2016, Journal of cellular and molecular medicine.

[32]  Ming Liu,et al.  MicroRNA-21 Regulates Non-Small Cell Lung Cancer Cell Invasion and Chemo-Sensitivity through SMAD7 , 2016, Cellular Physiology and Biochemistry.

[33]  Dong Chen,et al.  MicroRNA-21 modulates radiation resistance through upregulation of hypoxia-inducible factor-1α-promoted glycolysis in non-small cell lung cancer cells. , 2016, Molecular medicine reports.

[34]  F. Ciardiello,et al.  Mechanisms of resistance to EGFR-targeted drugs: lung cancer , 2016, ESMO Open.

[35]  J. Neuzil,et al.  MicroRNA-126 induces autophagy by altering cell metabolism in malignant mesothelioma , 2016, Oncotarget.

[36]  Wei Zhang,et al.  miRNA-296-3p modulates chemosensitivity of lung cancer cells by targeting CX3CR1. , 2016, American journal of translational research.

[37]  Xiaoju Wang,et al.  MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin , 2016, Cancer Cell International.

[38]  Ya‐Wen Cheng,et al.  Reduction of microRNA-184 by E6 oncoprotein confers cisplatin resistance in lung cancer via increasing Bcl-2 , 2016, Oncotarget.

[39]  H. Bai,et al.  Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21 , 2016, Chinese journal of cancer.

[40]  Jinchao Zhang,et al.  Triptolide reduces proliferation and enhances apoptosis of human non-small cell lung cancer cells through PTEN by targeting miR-21. , 2016, Molecular medicine reports.

[41]  Hong Zhang,et al.  MicroRNA-92a promotes growth, metastasis, and chemoresistance in non-small cell lung cancer cells by targeting PTEN , 2016, Tumor Biology.

[42]  Li-na Peng,et al.  miR-223 reverses the resistance of EGFR-TKIs through IGF1R/PI3K/Akt signaling pathway , 2016, International journal of oncology.

[43]  W. Cho,et al.  Implications of MicroRNAs in the Treatment of Gefitinib-Resistant Non-Small Cell Lung Cancer , 2016, International journal of molecular sciences.

[44]  M. Zhong,et al.  Inhibition of microRNA-196a might reverse cisplatin resistance of A549/DDP non-small-cell lung cancer cell line , 2016, Tumor Biology.

[45]  He Xiao,et al.  EGFR mutation status in plasma and tumor tissues in non-small cell lung cancer serves as a predictor of response to EGFR-TKI treatment , 2016, Cancer biology & therapy.

[46]  Qinghua Zhou,et al.  MicroRNA-338-3p suppresses metastasis of lung cancer cells by targeting the EMT regulator Sox4. , 2016, American journal of cancer research.

[47]  Zhongzhen Su,et al.  Downregulation of miR-101 contributes to epithelial-mesenchymal transition in cisplatin resistance of NSCLC cells by targeting ROCK2 , 2016, Oncotarget.

[48]  Yan-bin Zhao,et al.  MiR-181b regulates cisplatin chemosensitivity and metastasis by targeting TGFβR1/Smad signaling pathway in NSCLC , 2015, Scientific Reports.

[49]  Jun Yin,et al.  The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer , 2015, BMC Cancer.

[50]  M. Huang,et al.  Knockdown of microRNA-1323 restores sensitivity to radiation by suppression of PRKDC activity in radiation-resistant lung cancer cells. , 2015, Oncology reports.

[51]  Rui Hu,et al.  miR-106a promotes growth and metastasis of non-small cell lung cancer by targeting PTEN. , 2015, International journal of clinical and experimental pathology.

[52]  Lifang Yang,et al.  microRNA-548l is involved in the migration and invasion of non-small cell lung cancer by targeting the AKT1 signaling pathway , 2015, Journal of Cancer Research and Clinical Oncology.

[53]  B. Xiao,et al.  miR-25 modulates NSCLC cell radio-sensitivity through directly inhibiting BTG2 expression. , 2015, Biochemical and biophysical research communications.

[54]  Shi-huan Yu,et al.  miR‐99a Suppresses the Metastasis of Human Non‐Small Cell Lung Cancer Cells by Targeting AKT1 Signaling Pathway , 2015, Journal of cellular biochemistry.

[55]  Jie Gu,et al.  MicroRNA-7 sensitizes non-small cell lung cancer cells to paclitaxel , 2014, Oncology letters.

[56]  G. Calin,et al.  Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[57]  B. Jiang,et al.  Alteration in Mir-21/PTEN Expression Modulates Gefitinib Resistance in Non-Small Cell Lung Cancer , 2014, PloS one.

[58]  N. Zhong,et al.  Downregulation of PEBP4, a target of miR-34a, sensitizes drug-resistant lung cancer cells , 2014, Tumor Biology.

[59]  Jianjun Chen,et al.  MicroRNAs in cancer biology and therapy: Current status and perspectives , 2014, Genes & diseases.

[60]  W. De,et al.  Acquisition of radioresistance in docetaxel-resistant human lung adenocarcinoma cells is linked with dysregulation of miR-451/c-Myc-survivin/rad-51 signaling , 2014, Oncotarget.

[61]  Junjiang Fu,et al.  Epithelial to mesenchymal transition inducing transcription factors and metastatic cancer , 2014, Tumor Biology.

[62]  Jun Yin,et al.  miRNA 17 Family Regulates Cisplatin-Resistant and Metastasis by Targeting TGFbetaR2 in NSCLC , 2014, PloS one.

[63]  W. Guo,et al.  Up-regulation of microRNA-138 induce radiosensitization in lung cancer cells , 2014, Tumor Biology.

[64]  Wen-rong Gong,et al.  miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN. , 2013, Oncology reports.

[65]  A. Gemma,et al.  MiR-134/487b/655 Cluster Regulates TGF-β–Induced Epithelial–Mesenchymal Transition and Drug Resistance to Gefitinib by Targeting MAGI2 in Lung Adenocarcinoma Cells , 2013, Molecular Cancer Therapeutics.

[66]  G. Yousef,et al.  Clinical evaluation of microRNA expression profiling in non small cell lung cancer. , 2013, Lung cancer.

[67]  K. Seong,et al.  Rhamnetin and Cirsiliol Induce Radiosensitization and Inhibition of Epithelial-Mesenchymal Transition (EMT) by miR-34a-mediated Suppression of Notch-1 Expression in Non-small Cell Lung Cancer Cell Lines* , 2013, The Journal of Biological Chemistry.

[68]  E. Chuang,et al.  MicroRNA-449a Enhances Radiosensitivity in CL1-0 Lung Adenocarcinoma Cells , 2013, PloS one.

[69]  A. Noël,et al.  MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines , 2013, Cell Death and Disease.

[70]  A. Soltermann,et al.  Epithelial-mesenchymale Transition beim nichtkleinzelligen Bronchialkarzinom , 2012, Der Pathologe.

[71]  Yu Zhang,et al.  SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression. , 2012, Cancer research.

[72]  J. Sun,et al.  EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers , 2011, Nature Medicine.

[73]  N. Matsuura,et al.  Epithelial to mesenchymal transition is a determinant of sensitivity to chemoradiotherapy in non-small cell lung cancer. , 2011, The Annals of thoracic surgery.

[74]  Xi Chen,et al.  Serum microRNA signatures identified in a genome-wide serum microRNA expression profiling predict survival of non-small-cell lung cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[75]  M. Tsao,et al.  Overview of molecular testing in non-small-cell lung cancer: mutational analysis, gene copy number, protein expression and other biomarkers of EGFR for the prediction of response to tyrosine kinase inhibitors , 2009, Oncogene.

[76]  James B. Mitchell,et al.  Ionizing Radiation-Induced Oxidative Stress Alters miRNA Expression , 2009, PloS one.

[77]  A. Schetter,et al.  MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers , 2009, Proceedings of the National Academy of Sciences.

[78]  Joon-Oh Park,et al.  MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling , 2007, Science.

[79]  R. Wilson,et al.  EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[80]  C. Croce,et al.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[81]  Hao Jiang,et al.  miR-200c enhances sensitivity of drug-resistant non-small cell lung cancer to gefitinib by suppression of PI3K/Akt signaling pathway and inhibites cell migration via targeting ZEB1. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[82]  Zhu Jin,et al.  MicroRNA-138 regulates chemoresistance in human non-small cell lung cancer via epithelial mesenchymal transition. , 2016, European review for medical and pharmacological sciences.

[83]  Liang Han,et al.  MicroRNA-155 expression has prognostic value in patients with non-small cell lung cancer and digestive system carcinomas. , 2013, Asian Pacific journal of cancer prevention : APJCP.